Celyad Oncology S.A. - ROE
0QFK.L
Celyad Oncology S.A., a clinical-stage biopharmaceutical company headquartered in Mont-Saint-Guibert, Belgium, specializes in the discovery and development of innovative chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its pipeline includes several key candidates: CYAD-101, an allogeneic CAR-T, is currently undergoing a Phase 1b clinical trial for metastatic colorectal cancer. For relapsed/refractory multiple myeloma, the company is evaluating CYAD-211, an shRNA-based allogeneic CAR-T candidate, in a Phase 1 study. Additionally, CYAD-02, an autologous CAR-T, is in Phase 1 clinical trials for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. ...[Read more]
Industry
Medical - Pharmaceuticals
IPO Date
2014-01-08
Stock Exchange
LSE
Ticker
0QFK.L
PE Ratio
[-1.12]
ROE
[-242.11%]
Current Ratio
[1.92]
Dividend Yield
[0%]
Enterprise Value
[9.48M]
Dividend History
The ROE as of July 2026 (TTM) for Celyad Oncology S.A. (0QFK.L) is -242.11%
According to Celyad Oncology S.A.’s latest financial reports and current stock price. The company's current ROE is -242.11%. This represents a change of -524.26% compared to the average of 57.06% of the last 4 quarters.
Celyad Oncology S.A. (0QFK.L) Historical ROE (quarterly & annually)
How has 0QFK.L ROE performed in the past?
The mean historical ROE of Celyad Oncology S.A. over the last ten years is -140.30%. The current -242.11% ROE has changed 72.56% with respect to the historical average. Over the past ten years (40 quarters), 0QFK.L's ROE was at its highest in in the June 2013 quarter at 572.93%. The ROE was at its lowest in in the June 2023 quarter at -367.03%.
Average
-140.30%
Median
-61.76%
Minimum
-948.23%
Maximum
36.13%
Celyad Oncology S.A. (0QFK.L) ROE by Quarter and Year
Discovering the peaks and valleys of Celyad Oncology S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.46%
Maximum Annual ROE = 36.13%
Minimum Annual Increase = -126.96%
Minimum Annual ROE = -948.23%
| Year | ROE | Change |
|---|---|---|
| 2025 | 34.07% | -5.69% |
| 2024 | 36.13% | -126.96% |
| 2023 | -134.01% | -85.87% |
| 2022 | -948.23% | 1.46% |
| 2021 | -60.75% | 9.45% |
| 2020 | -55.51% | -11.56% |
| 2019 | -62.76% | -6.78% |
| 2018 | -67.33% | -43.25% |
| 2017 | -118.64% | 356.76% |
| 2016 | -25.97% | -0.55% |
Celyad Oncology S.A. (0QFK.L) Average ROE
How has 0QFK.L ROE performed in the past?
The current ROE of Celyad Oncology S.A. (0QFK.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-21.27%
5-year avg
-214.56%
10-year avg
-140.30%
Celyad Oncology S.A. (0QFK.L) ROE vs. Peers
How is 0QFK.L’s ROE compared to its peers?
Celyad Oncology S.A.’s ROE is
| Company | ROE | Market cap |
|---|
Build a custom stock screener for Celyad Oncology S.A. (0QFK.L) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celyad Oncology S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Celyad Oncology S.A. (0QFK.L) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Celyad Oncology S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Celyad Oncology S.A.'s ROE?
How is the ROE calculated for Celyad Oncology S.A. (0QFK.L)?
What is the highest ROE for Celyad Oncology S.A. (0QFK.L)?
What is the 3-year average ROE for Celyad Oncology S.A. (0QFK.L)?
What is the 5-year average ROE for Celyad Oncology S.A. (0QFK.L)?
How does the current ROE for Celyad Oncology S.A. (0QFK.L) compare to its historical average?